Compound ID | 1956
Synonym(s): XNW4107
Class: Beta-lactamase inhibitor (non-beta-lactam beta-lactamase inhibitor, diazabicyclooctane [DBO])
Details of activity: | DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D beta-lactamases. No intrinsic antibacterial activity |
Combined with other compounds: | Yes |
Description: | Synthetic compound. In clinical development in fixed combination with imipenem/cilastatin |
Institute where first reported: | Suzhou Sinovent Pharmaceuticals |
Year first mentioned: | 2021 |
Highest developmental phase: | Phase 3 |
Development status: | Active (as of 2024) |
Chemical structure(s): | |||||||||||||
|
|
||||||||||||
|
|
External links: | |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/158340749 |
PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/104838 |
Guide to Pharmacology: | funobactam |
Citation: | https://www.sciencedirect.com/science/article/pii/S2213716522001722 |